| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424233100 | Adenoviridae, adeno-like virus, or Parvoviridae (e.g., adenovirus, canine parvovirus, mink enteritis virus, hemorrhagic enteritis virus, feline panleukopenia virus, egg drop syndrome virus, etc.) | 33 |
| 20080206283 | Vaccine Against Sars - The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing antibodies. | 08-28-2008 |
| 20080241189 | Sequential Delivery Of Immunogenic Molecules Via Adenovirus And Adeno-Associated Virus-Mediated Administrations - An immunogenic regimen is provided. The regimen involves sequential administration of a recombinant adenoviral vector and a recombinant adeno-associated viral vector, each of which delivers a heterologous expression cassette encoding the same immunogenic product, or a cross-reactive immunogenic product. Also provided are products containing the vectors for use in the regimen of the invention. | 10-02-2008 |
| 20090087455 | ADIPOGENIC ADENOVIRUSES AS A BIOMARKER FOR DISEASE - A vaccine may be administered to a subject to prevent-related disease due to an adipogenic adenovirus. The vaccine may stimulate the production of adipogenic adenovirus neutralizing antibodies in the subject such that the adipogenic adenovirus neutralizing antibodies prevent obesity-related disease due to an adipogenic adenovirus. | 04-02-2009 |
| 20090117156 | GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A - This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS). | 05-07-2009 |
| 20100047282 | METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES - The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form. | 02-25-2010 |
| 20100104600 | Methods and Compositions for Increasing Tissue Tropism of Recombinant Adenoviral Vectors - Methods are provide to allow for the preparation of adenoviral vectors with altered tropism. Compositions comprising such vectors and methods of use thereof also are provided. | 04-29-2010 |
| 20100129405 | ISOLATION, CLONING AND CHARACTERIZATION OF NEW ADENO-ASSOCIATED VIRUS (AAV) SEROTYPES - The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles. | 05-27-2010 |
| 20100166799 | ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO - The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject. | 07-01-2010 |
| 20100183673 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS - Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 07-22-2010 |
| 20100203083 | MUTATED STRUCTURAL PROTEIN OF A PARVOVIRUS - The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure. | 08-12-2010 |
| 20100260799 | SIMIAN SUBFAMILY C ADENOVIRUSES SAdV-40, -31, AND -34 AND USES THEREOF - A recombinant vector comprises simian adenovirus SAdV-31 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-31 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 10-14-2010 |
| 20100260800 | AVV Vectors and Methods - The invention relates to Adeno-associated virus vectors. In particular, it relates to Adeno-associated virus vectors with modified capsid proteins and materials and methods for their preparation and use. | 10-14-2010 |
| 20100272753 | Recombinant Adenovirus Vaccines - Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria. | 10-28-2010 |
| 20100297177 | MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES - The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use. | 11-25-2010 |
| 20110059135 | Capsid-Incorporated Antigen for Novel Adenovirus Vaccine - This invention pertains to tropism-modified adenoviral vectors optimized for antigen delivery that induced both humoral and cellular immune responses, as well as a method of constructing and using such vectors. The vectors of the present invention may incorporate an epitope or an antigen into a capsid protein. Methods for treating of a host with an effective amount of adenovirus vector of the present invention are also provided. | 03-10-2011 |
| 20110091502 | HUMAN PARVOVIRUS: HUMINK PARVOVIRUS - Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Humink parvovirus, and variants thereof. Also provided are methods of detecting the Humink parvovirus and diagnosing Humink parvovirus infection, methods of treating or preventing Humink parvovirus infection, and methods for identifying anti-Humink parvovirus compounds. | 04-21-2011 |
| 20110123569 | VACCINE DIRECTED AGAINST ADENOVIRUS SEROTYPE 14 - The invention is directed to a live attenuated serotype 14 adenovirus, and a method of inducing an immune response against a serotype 14 adenovirus in a mammal using the live attenuated serotype 14 adenovirus. | 05-26-2011 |
| 20110135688 | Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors - This invention relates to methods of increasing titer of recombinant PAdV-3 produced in porcine host cells by increasing PAdV-3 encapsidation efficiency and compositions comprising the same. More particularly, the invention describes optimized recombinant PAdV-3 vectors in which the packaging signal has been optimized. In particular, the optimization involves increasing the number of packaging elements in the PAdV-3 viral genome. | 06-09-2011 |
| 20110150930 | Recombinant viral-based malaria vaccines - Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different | 06-23-2011 |
| 20110171262 | PARVOVIRAL CAPSID WITH INCORPORATED GLY-ALA REPEAT REGION - Parvoviral capsid with incorporated Gly-Ala repeat region The present invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a parvoviral VP1, VP2 and VP3 capsid proteins comprising an immuno evasion repeat sequence. In addition, the present invention provides a cell comprising such construct, a parvoviral virion comprising a capsid protein that comprises an immune evasion repeat sequence, use of that parvoviral virion in gene therapy and a pharmaceutical composition comprising such parvoviral virion. | 07-14-2011 |
| 20110189234 | ADENOVIRUS PARTICLES HAVING A CHIMERIC ADENOVIRUS SPIKE PROTEIN, USE THEREOF AND METHODS FOR PRODUCING SUCH PARTICLES - The present invention is concerned with means and methods for producing adenovirus particles comprising a chimeric adenovirus spike protein that essentially lacks a functional knob domain. One aspect of the invention is concerned with a method for producing adenovirus particles comprising providing cells that are permissive for adenovirus replication with an adenovirus vector, with nucleic acid encoding said chimeric adenovirus spike protein and with nucleic acid encoding at least one adenovirus E3 region protein or a functional part, derivative and/or analogue thereof, said method further comprising culturing said permissive cells to allow for at least one replication cycle of said adenovirus virus and harvesting said adenovirus particle. | 08-04-2011 |
| 20110189235 | Adipogenic Adenoviruses As A Biomarker For Disease - A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject. | 08-04-2011 |
| 20110217332 | Chimpanzee Adenovirus Vaccine Carriers - The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer. | 09-08-2011 |
| 20120039939 | COMPOSITIONS AND METHODS FOR VACCINE AND VIRUS PRODUCTION - The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus. | 02-16-2012 |
| 20120219590 | FORMULATIONS USEFUL FOR SPRAY DRYING VACCINES - The present invention is directed to formulations for spray-drying viral particles, methods for spray drying such compositions, and pharmaceutical compositions and vaccines comprising the present spray-dried powders. The present formulations advantageously provide for spray-drying viral particles at low temperatures, thereby producing spray-dried viral powders having viral infectivities comparable to those of powders prepared by lyophilization of comparable formulations. The methods and compositions described herein advantageously provide substantially higher throughput and production rates for the production of viral powders. Further, spray-dried viral powders incorporating enteric polymers can be produced at low temperatures. | 08-30-2012 |
| 20120244187 | Adenovirus Infection In Animals - Animals have tested positive for unsuspected natural infection with lipogenic adenoviruses. Methods for testing animals, including food stuffs and experimental animals, for lipogenic adenovirus infection are disclosed. Exposure to infected meat and animal co-products may cause health and safety issues. As a result of lipogenic adenovirus infection in experimental animal species, research related to fat or glucose metabolism, energy metabolism, cancer biology, and obesity research may have been or may be negatively affected or compromised. | 09-27-2012 |
| 20120263756 | VACCINES CONTAINING CANINE PARVOVIRUS GENETIC VARIANTS - Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging canine parvovirus variants. | 10-18-2012 |
| 20130052226 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING A HUMAN PARVOVIRUS INFECTION - The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions. | 02-28-2013 |
| 20130273109 | METHOD FOR GENERATING A PARVOVIRUS B19 VIRUS-LIKE PARTICLE - The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids. | 10-17-2013 |
| 20140170187 | COMPOSITIONS AND METHODS FOR ASSESSING FUNCTIONAL IMMUNOGENICITY OF PARVOVIRUS VACCINES - The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection. | 06-19-2014 |
| 20140348876 | Stable Aqueous Formulations of Adenovirus Vectors - The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation. | 11-27-2014 |
| 20150056251 | AAV-DIRECTED PERSISTENT EXPRESSION OF AN ANTI-NICOTINE ANTIBODY GENE FOR SMOKING CESSATION - The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody that binds to nicotine or a nicotine analog, or an antigen-binding fragment thereof. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal. | 02-26-2015 |
| 20180021458 | Optimized RPE65 Promoter and Coding Sequences | 01-25-2018 |
